AI Article Synopsis

  • DC is a medicinal plant from the Fabaceae family, used for various health issues like stomach problems, malaria, and breast milk stimulation.
  • Column chromatography of the plant's stem bark led to the isolation of eight chemical compounds, with their structures analyzed using NMR, IR, and MS techniques.
  • Testing showed that most compounds had low toxicity in breast cancer and non-cancerous cell lines, but one compound, (3)-3-acetoxyolean-12-en-28-oic acid, was more toxic to hormone receptor-positive breast cancer cells than to non-cancerous cells.

Article Abstract

DC is an indigenous medicinal plant belonging to the genus of the Fabaceae family. It is used to treat stomach problems, headaches, mouth ulcers, malaria, blackwater fever, gonorrhea, ringworm, diarrhea, heavy menstruation, and breast milk stimulation. Column chromatography of the stem bark extracts resulted in the isolation of eight compounds, which included friedelan-3-one (), 3α-hydroxyfriedel-2-one (), 3-hydroxyfriedel-3-en-2-one (), lup-20(29)-en-3-ol (), Stigmasta-5-22-dien-3-ol (), 4--methylangolensis (), (3)-3-acetoxyolean-12-en-28-oic acid (), and tetradecyl (E)-ferulate (). The structures were established based on NMR, IR, and MS spectroscopic analyses. Triple-negative breast cancer (HCC70), hormone receptor-positive breast cancer (MCF-7), and non-cancerous mammary epithelial cell lines (MCF-12A) were used to test the compounds' cytotoxicity. Overall, the compounds showed either no toxicity or very low toxicity to all three cell lines tested, except for the moderate toxicity displayed by lupeol () towards the non-cancerous MCF-12A cells, with an IC value of 36.60 μM. Compound (3)-3-acetoxyolean-12-en-28-oic acid () was more toxic towards hormone-responsive (MCF-7) breast cancer cells than either triple-negative breast cancer (HCC70) or non-cancerous breast epithelial (MCF-12A) cells (IC values of 83.06 vs. 146.80 and 143.00 μM, respectively).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10818308PMC
http://dx.doi.org/10.3390/plants13020301DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
cancer cells
8
3-3-acetoxyolean-12-en-28-oic acid
8
triple-negative breast
8
cancer hcc70
8
cell lines
8
mcf-12a cells
8
breast
7
cancer
5
phytochemicals cytotoxic
4

Similar Publications

Introduction: The use of taxanes in the adjuvant setting of early breast cancer (BC) confers survival benefits, however, their role in older patients merits further study. This retrospective pooled analysis of randomized controlled trials conducted by the Hellenic Oncology Research Group (HORG) aims to assess the efficacy and safety of taxane-based adjuvant chemotherapy in older women with BC.

Materials And Methods: Five phase III trials containing a taxane, conducted by HORG between 1995 and 2013, were included in a patient-data pooled analysis.

View Article and Find Full Text PDF

Background: As part of the 2021 changes to breast reconstruction CPT codes, the Relative Value Scale Update Committee (RUC) recommended adjustments to work RVUs (wRVUs) based on newly surveyed intraoperative times. Our objective was to gauge the accuracy of operative time and wRVU adjustments using national data as a benchmark.

Methods: We queried the National Surgical Quality Improvement Program (NSQIP) database for operative times from 2005-2021 for reevaluated CPT codes.

View Article and Find Full Text PDF

Objective: Evaluate the effect of white noise intervention on sleep quality and immunological indicators of patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).

Methods: From January 2020 to December 2022, 104 newly diagnosed female patients (the number of people who met the inclusion criteria) with breast cancer who were confirmed to be preoperative NAC by puncture pathology were selected for a randomised single-blind trial. The patients were randomly divided into an observation group and a control group, with 52 cases in each group.

View Article and Find Full Text PDF

Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.

Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.

View Article and Find Full Text PDF

Background: Breast cancer is the most common cancer in women, and mammogram screening can reduce breast cancer mortality. Healthcare providers' perspectives can have an impact on encouraging females to attend mammogram screening.

Objective: To understand healthcare providers' (HCPs) perspectives in initiating discussion on mammogram screening, and their perceived barriers and enablers to screening in women.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!